Figure 4
AMACR1 peptide-specific CTL induction from PBMCs of HLA-A24-positive prostate cancer patients. PBMCs of HLA-A24-positive prostate cancer patients (cases 4, 5 and 6) were stimulated four times with three kinds of AMACR peptide (AMACR1-3)-pulsed APCs and their cytotoxic activities were examined by 51Cr release assay at the indicated effector/target ratios. AMACR1 peptide-pulsed T2-A*2402 cells served as target cells. Non-pulsed T2-A*2402 cells were used as negative control target cells. K562 target cells were used for monitoring natural killer cell activity and lymphokine-activated nonspecific cytotoxicity.